Home

H. HIV/AIDS and Other Retroviruses, Including Resistance

 

Meet-the-Experts

 

Can We Safely Simplify Antiretroviral Therapy in Treatment-Experienced Patients?

This session will use case studies and discuss of recent data to explore options for the simplification of antiretroviral therapy in patients who are on antiretroviral treatment and have varying levels of previous ARV treatment and HIV-1 resistance to ARVs. Over the last several years there has been an introduction of several new, well tolerated, highly active agents that are relatively simple to administer along with the introduction of two new fixed dose combination tablets that provide a full antiretroviral treatment regimen in a single pill. The risks and benefits of therapy simplification will be discussed.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

• Discuss several potential scenarios in which patients suppressed on effective but complicated antiretroviral therapy can have their regimen simplified without compromising the success of the treatment regimen;
• Summarize information on new agents and new assays that may increase our ability to simplify antiretroviral therapy even in patients who have extensive previous treatment experience; 
• Assess the potential risks and benefits of therapy simplification for specific patient types; and 
• Evaluate the role of new fixed dose combination tablets in simplification of successful but cumbersome or complex regimens in treatment experienced patients. 

Experts:
Pedro Cahn, MD, PhD; Fundación Huesped, Buenos Aires, Argentina.
Sharon Walmsley, MSc, FRCPC; Toronto Gen. Hosp., Toronto, Canada.

 

How Do I Treat HCV in HIV/HCV Co-Infected Patients ?

Direct acting antivirals are now available for the treatment of HCV-infection, but there are many questions around the best time to use these drugs in patients co-infected with HIV, their efficacy and their safety. Physicians should be also knowledgeable about potential pharmacokinetic interactions between HIV and HCV drugs. Therefore, the optimal management of HCV-infection in HIV-infected individuals needs to be discussed.

Upon completion of this Meet-the-Expert Session, the participant should be able to:

• Review recent data with direct acting anti-HCV drugs for the treatment of HCV-infection;
• Discuss the unsettled issues and pitfalls of using DAAs for the treatment of HCV-infection in HIV-infected patients; and 
• Describe the most significant drug-drug interactions between anti-HCV and HIV drugs. 

Experts:
Charles W. Flexner, MD; Johns Hopkins Univ. Sch. of Med., Baltimore, MD.
Vincent Soriano, MD, PhD; Univ. Complutense of Madrid, Madrid, Spain.

 

Management of Antiretroviral Therapy-Induced Bone Toxicity

Management of bone disease in the HIV-infected patient not only requires awareness of the effects of HIV itself and antiretroviral agents on bone but also an understanding of traditional risk factors and the interactions between host –infection- medications. One of the more common secondary causes of bone disease is Vitamin D Deficiency. This session will highlight the recommended screening strategies for bone disease, how to interpret DEXA scans, distinguish between osteoporosis vs osteomalacia and current recommendations for treatment of vitamin deficiency and bone disease.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

• Describe bone complications resulting from HIV infection and its treatment;
• Distinguish between osteoporosis and osteomalacia; 
• Discuss the role Vitamin D may play in the development of HIV-associated bone disease; and 
• Discuss the management of HIV associated bone disease. 

Experts:
Grace A. McComsey, MD; Case Western Reserve Univ. Sch. of Med., Cleveland, OH.
Pablo Tebas, MD; Univ. of Pennsylvania, Philadelphia, PA.

 

Prevention of Anal Cancer in HIV-Infection: From Early Detection to Vaccination

HIV infected persons are at higher risk of developing serious human papilloma virus (HPV) related malignancies. This session will discuss the role of HPV vaccination in both the prevention of anal dysplasia and as a therapeutic intervention. Case based discussions will assist the attendee to learn risk factors associated with development of anal dysplasia and who would most likely to benefit from vaccination.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

• Identify risk factors for anal dysplasia in HIV infection;
• Discuss the role of HPV vaccination in HIV infected persons; and 
• Discuss the role of HPV vaccine as a therapeutic intervention for anal lesions. 

Experts:
Erna M. Kojic, MD; Warren Alpert Med. Sch., Brown Univ., Providence, RI.
Joel Palefsky, MD; Univ. of California, San Francisco, CA.

 

Symposia

 

Current Issues in HIV-Associated Opportunistic Diseases

Despite major advances in the treatment of HIV-infection, questions still remain around the best time and consequences of antiretroviral therapy initiation in patients with opportunistic diseases. Also, the optimal management of major opportunistic diseases in HIV-infected individuals needs to be discussed.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss new data for the diagnosis and management of Castleman disease in patients with HIV-infection;
• Discuss the challenges of using antiretrovirals for the treatment of cryptococcal meningitis; Review current knowledge on the prophylaxis and management of tuberculosis in HIV-infection; and 
• Discuss the impact of HIV-infection on the incidence, clinical presentation and management of malaria. 

Conveners:
Jean-michel Molina, MD; Saint Louis Hosp. and Univ. of Paris, Paris, France.
Richard E. Chaisson, MD; John Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.

Presentations:
Diagnosis and Management of Castleman Disease
Eric Oksenhendler, MD; Univ. of Paris Diderot, Paris, France.

Use of Antiretrovirals in Patients with Cryptococcal Meningitis
David R. Boulware, MD, MPH; Univ. of Minnesota, Minneapolis, MN.

Prevention and Treatment of Tuberculosis in HIV-Infected Individuals
Richard E. Chaisson, MD; John Hopkins Univ. Ctr. for Tuberculosis Res., Baltimore, MD.

HIV and Malaria
Johanna Daily, MD; Albert Einstein Coll. of Med., Bronx, NY.

 

Update on HIV-Associated Co-Morbidities

This session with provide a state of the art discussion on co-morbidities and complications associated with HIV including an update on solid organ transplant. A summary of the abstracts from the World AIDS Conference will be provided. In addition, an overview of CNS complications will be presented as well as an interactive case based discussion on the new recommendations for the management for syphilis.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss the epidemiology and outcomes of persons with HIV infection who receive organ transplants;
• Review current knowledge of CNS complications associated with HIV infection; 
• Identify the new diagnostic and treatment guidelines for of syphilis in HIV infected persons; and 
• Review the data presented on co-morbidities at the World AIDS Conference 2012. 

Conveners:
Judith Aberg, MD; New York Univ., New York, NY.
Esteban Martínez, MD; Univ. of Barcelona, Barcelona, Spain.

Presentations:
Epidemiology and Outcomes of Organ Transplantation in HIV
Peter Stock, MD, PhD; Univ. of California, San Francisco, CA.

CNS Complications of HIV
Serena S. Spudich, MD; Yale Univ. Sch. of Med., New Haven, CT.

Syphilis and HIV: A Case Based Discussion
Kimberly Workowski, MD; Emory Univ., Atlanta, GA.

Update from the World AIDS Conference
Esteban Martínez, MD; Univ. of Barcelona, Barcelona, Spain.

 

What’s New in Antiretroviral Therapy

This session with provide a state of the art update on antiretroviral therapy for both HIV treatment and prevention for clinicians, clinical scientists, pharmacologists, virologists and drug developers. Areas of focus will include what combinations of agents to use as initial therapy and novel drugs and treatment strategies in development. Use of antiretrovirals for pre-exposure prophylaxis (PrEP) will be discussed and recent discordant results will be reviewed. Highlights from the recent literature and summer World AIDS Conference will be presented.

Upon completion of this Symposium Session, the participant should be able to:

• Discuss several recommended initial antiretroviral regimens for the treatment of HIV-1 infection and identify potential patient types for which one regimen may be more suited than another;
• Summarize information of new antiretroviral agents and antiretroviral treatment strategies that are in development for the treatment of HIV-1 infection;
• Compare data from several large studies of pre-exposure prophylaxis studies using antiretrovirals for the prevention of HIV infection and consider which at risk individuals may benefit from PrEP for HIV prevention; and 
• Review the most important antiretroviral research studies that were published in 2012 or were presented at the 2012 International AIDS conference in Washington DC. 

Conveners:
Roy Gulick, MD; Cornell Univ. Sch. of Med., New York, NY.
Joseph Eron Jr., MD; Univ. of North Carolina, Chapel Hill, NC.

Presentations:
Antiretroviral Therapy 2012: What to Start?
Joel E. Gallant, MD, MPH; Johns Hopkins Univ. Sch. of Med., Baltimore, MD.

New Antiretrovirals and Novel Strategies for the Treatment of HIV-1 Infection
Patrick Yeni, MD; Hosp. Bichat-Claude Bernard and Xavier Bichat Med. Sch., Paris, France.

Pre-Exposure Prophylaxis (PrEP) for HIV-1: Where Have We Been and Where are We Going?
Jared Baeten, MD; Univ. of Washington Seattle Sch. of Publ. Hlth., Seattle, WA.

Top Papers in Antiretroviral Therapy: Including Key Presentations from the 2012 International AIDS AIDS Conference
Roy Gulick, MD; Cornell Univ. Sch. of Med., New York, NY.

 

Interactive Symposium

 

Advances in HIV and HCV Management

Developed in cooperation with the International Anti-Retroviral Society USA (IAS-USA)

This interactive, case-based session is designed to provide learners with current data for managing specific situations in patients with HIV infection. Experts in the field will address challenging cases around patient management including, pre-exposure prophylaxis, care of the older HIV patient, co-morbidities, pregnancy, treatment-experienced patients, and management of HCV infection with direct-acting antivirals. These presentations will enable participants to learn through the discussion of clinically-relevant scenarios.

Upon completion of this Interactive Symposium Session, the participant should be able to:

• Design, implement, and evaluate antiretroviral therapy in selected patients, including those who are pregnant, older, or treatment-experienced; and
• Design direct-acting antiviral regimens that effectively treat HCV infection in HIV/HCV coinfected patients.

Presentations:
Update on Guidelines and Issues for Initiating Antiretroviral Therapy in HIV Infection
Ann C. Collier, MD; Univ. of Washington Sch. of Med., Seattle, WA.

Clinical Management of Antiretroviral Therapy-Experienced Patient
Pablo Tebas, MD; Univ. of Pennsylvania, Philadelphia, PA.

Clinical Management of HCV Infection: A New Paradigm
David L. Wyles, MD; Univ. of California, San Diego, CA.